By Alexander Pahlavi
BOSTON—A short-course treatment for those with HIV was as safe and effective in preventing active tuberculosis (TB) as current treatments with lengthier timetables, according to results presented at CROI 2018 (abstract 37LB).
A four-week daily regimen of rifapentine (Priftin, sanofi-aventis) and isoniazid (1HP) proved non-inferior to a nine-month daily regimen of isoniazid (9H) for preventing TB, TB death or death from unknown cause in adults and adolescents with